Abstract:Purpose: Treatment for bilateral breast cancer with radiation therapy is technically challenging. We evaluated the clinical and dosimetric outcomes of a small series of patients with synchronous bilateral breast cancer, including a photon dosimetric comparison, to identify optimal treatment planning approaches. Materials and methods: We reviewed a registry of patients (simultaneously) diagnosed with synchronous bilateral breast cancers who underwent postoperative definitive adjuvant proton therapy at our institution between 2012 and 2021. All patients were treated with double-scattered proton or pencil-beam scanning therapies. For comparison, intensity-modulated radiation therapy photon plans optimized for organ sparing and coverage were generated after treatment. Results: Six patients were included. The median patient age was 66 years; all were female with no history of breast cancer or radiation therapy. Two (33%) patients received breast/chest wall-only treatments, 1 (17%) required breast plus level I axillary treatment to one side and breast plus regional nodal irradiation (RNI) to the other, and 3 (50%) received bilateral breast/chest plus RNI; dosimetric results are reported for each group's median. Analysis showed clinical target coverage was comparable between proton and photon techniques (V95% of 96.4% with proton, 97.8% with photon). However, protons could deliver superior organ sparing at clinically relevant dose metrics for virtually all structures: a 6.7 Gy absolute reduction in the mean heart dose (7.5 Gy with photons to 0.7 Gy with protons), a 47% to 57% relative reduction in D0.1cm3 to coronary arteries, a 54% relative reduction in lung V20 Gy, and an absolute 7.6 Gy reduction to the brachial plexus. There was also greater esophagus and spinal cord sparing. The overall survival rate was 100% at 1.5 years of median follow-up (0.5-4.9), and all patients were free of disease. For toxicity, all patients had some form of acute side effects: 66% experienced grade 2 breast/chest pain or soreness; 100% had grade 2 radiation dermatitis or skin induration; 33% had grade 2 fatigue; and 17% had grade 2 esophagitis (per the Common Terminology Criteria for Adverse Events [CTCAE] version 5.0; US National Cancer Institute, Bethesda, Maryland). Subacute toxicity (within 6 months) was observed for 17% of patients with delayed onset of grade 3 dermatitis in the setting of preexisting lupus, 17% with a delayed surgical wound complication, and 17% with grade 2 soft tissue fibrosis. No grade 4 or 5 events were observed. Conclusions: Substantial dose reductions to multiple organs at risk while maintaining target coverage make proton the preferred modality for bilateral breast cancer treatment when available.

Proton therapy for breast cancer: Reducing toxicity

Future Perspectives of Proton Therapy in Minimizing the Toxicity of Breast Cancer Radiotherapy

Proton Therapy in Breast Cancer: A Review of Potential Approaches for Patient Selection

Proton therapy for prostate cancer: current state and future perspectives

New Frontiers in Proton Therapy: Applications in Cancers.

The Evolution of Proton Beam Therapy: Current and Future Status (Review)

Enhancing Proton Therapy Efficacy Through Nanoparticle-Mediated Radiosensitization

Proton therapy toxicity outcomes for localized prostate cancer: Long-term results at a comprehensive cancer center

Proton Therapy for Bilateral Breast Cancer Maximizes Normal-Tissue Sparing

Proton beams in cancer treatments: Clinical outcomes and dosimetric comparisons with photon therapy

Proton therapy for locally advanced non-small cell lung cancer

Cost-effectiveness of Using Protons for Breast Irradiation Aiming at Minimizing Cardiotoxicity: A Risk-Stratification Analysis

Proton therapy for head and neck cancer: expanding the therapeutic window

Dosimetric Comparison of Intensity-Modulated Proton Radiotherapy Versus Intensity-Modulated Photon-Based Radiotherapy for Breast Cancer

Analysis of the Proton Therapy Controlling System and Application

A Systematic Review of Treatment-Related Side Effects and Toxicities

Radiation-Induced Toxicity Risks in Photon Versus Proton Therapy for Synchronous Bilateral Breast Cancer

Particle Therapy for Cancers: a New Weapon in Radiation Therapy.

Proton and heavy ion radiotherapy: the context and challenges

Proton Improves BED&nbsp;Compared With Photon Beam-based Partial Stereotactic Ablative Boost Radiotherapy for Large Non-small Cell Lung Cancer

Proton Improves BED Compared With Photon Beam-based Partial Stereotactic Ablative Boost Radiotherapy for Large Non-small Cell Lung Cancer